Archive for October 19, 2009

Reconsidering Some Approved Antimicrobial Agents for Tuberculosis

Antimicrobial Agents and Chemotherapy  1 Nov 2009  V.53  N.11  p.4577-4579

COMMENTARY

Lowell S. Young*

Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute

Full text

http://aac.asm.org/cgi/content/full/53/11/4577

PDF

http://aac.asm.org/cgi/reprint/53/11/4577

October 19, 2009 at 11:48 am Leave a comment

Tuberculosis and Trimethoprim-Sulfamethoxazole

Antimicrobial Agents and Chemotherapy  1 Nov 2009  V.53  N.11  p.4789-4793

Pierre Forgacs,1* Nancy L. Wengenack,2 Leslie Hall,2 Sarah K. Zimmerman,3 Mark L. Silverman,4 and Glenn D. Roberts2

Departments of Infectious Diseases and Research,1 Clinical Microbiology,3 Anatomic Pathology, Lahey Clinic Medical Center, Burlington, Massachusetts,4 Department of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota2

The sulfonamides were the first drugs with antituberculous effects. Their use was abandoned and basically forgotten with the advent of streptomycin and isoniazid combination treatment. There is a widespread belief, apparently based on testing a single isolate on questionable media, that Mycobacterium tuberculosis is resistant to trimethoprim-sulfamethoxazole (TMP-SMX). We saw a complex immunocompromised patient with tuberculosis who was initially treated with TMP-SMX without antituberculous drugs and defervesced on this treatment. An isolate of M. tuberculosis from this patient was found to be sensitive to TMP-SMX. We examined how frequently M. tuberculosis is sensitive to TMP-SMX. Isolates were tested for susceptibility to TMP-SMX on supplemented Middlebrook 7H10 plates. We found that 43 of 44 (98%) isolates of M. tuberculosis were susceptible to the combination of 1 µg/ml of TMP and 19 µg/ml of SMX (1/19 µg/ml). Thus, the vast majority of our M. tuberculosis isolates were susceptible to TMP-SMX at an MIC similar to that for Mycobacterium kansasii, Mycobacterium marinum, and sensitive rapidly growing mycobacteria, organisms successfully treated with TMP-SMX as part of the treatment regimen. It is possible that TMP-SMX may be useful in treating patients with multiple-drug-resistant and extended drug-resistant tuberculosis. We feel that a clinical trial looking at the effectiveness of TMP-SMX as an antituberculous drug is worthwhile.

abstract

http://aac.asm.org/cgi/content/abstract/53/11/4789

PDF

http://aac.asm.org/cgi/reprint/53/11/4789

October 19, 2009 at 11:46 am Leave a comment


Calendar

October 2009
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Posts by Month

Posts by Category